Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02920450 · ClinicalTrials.gov registry record · Phase 1
Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
A Phase 1 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02920450 is a Phase 1 study that was terminated before completion, run by University of Florida. The registered enrollment target is 3 participants.
The verdict
NCT02920450, a Phase 1 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if the study drug, Gedatolisib (PF-05212384), given in combination with paclitaxel and carboplatin will work against unresectable non-small cell lung cancer.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Gedatolisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2019-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02920450
The ClinicalTrials.gov registry entry for NCT02920450 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02920450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02920450 about?
NCT02920450 is a clinical study titled "Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)". The purpose of this research study is to determine if the study drug, Gedatolisib (PF-05212384), given in combination with paclitaxel and carboplatin will work against unresectable non-small cell lung cancer.
What is the current status of trial NCT02920450?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-09-25. Estimated completion is 2019-04-04.
What interventions are being tested in trial NCT02920450?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Gedatolisib (DRUG).
Who is sponsoring clinical trial NCT02920450?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.